Acquisition

GlaxoSmithKline (GSK) is to acquire biopharmaceutical company Sierra Oncology in a deal worth £1.5 billion, the company has announced.   Sierra Oncology  Sierra Oncology is a late-stage company focused on targeted therapies for the treatment of rare forms of cancer. The company’s lead asset, momelotinib, is being investigated as a treatment for myelofibrosis – a fatal […]

Tokyo-based Takeda Pharmaceutical has optioned to acquire Adaptate Biotherapeutics, a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells.   The acquisition   Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programmes. Adaptate’s γδ T cell engagers are designed to specifically modulate γδ T cell-mediated immune responses at tumour sites while sparing […]